Analysts Issue Forecasts for COAG Q2 Earnings

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Hemab Therapeutics in a note issued to investors on Wednesday, June 17th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.69) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. HC Wainwright also issued estimates for Hemab Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($3.12) EPS, FY2027 earnings at ($2.69) EPS, FY2028 earnings at ($3.48) EPS, FY2029 earnings at ($3.81) EPS and FY2030 earnings at ($2.71) EPS.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Other equities research analysts also recently issued research reports about the stock. Evercore initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Wedbush initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price target on the stock. Finally, Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.40.

Hemab Therapeutics Price Performance

Shares of COAG stock opened at $29.24 on Friday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $36.61.

Insider Activity at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This trade represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders purchased 2,970,541 shares of company stock valued at $55,459,603.

Key Stories Impacting Hemab Therapeutics

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage on Hemab Therapeutics with a Buy rating and a $40 price target, implying meaningful upside from recent trading levels. The firm also published estimates that keep the company in a loss-making profile for several years, but the optimistic rating appears to be the main takeaway for investors. HC Wainwright coverage on COAG
• Positive Sentiment: Major shareholder Ra Capital Management continued adding to its stake, buying additional shares at around $24.89-$24.98 per share. Repeated insider purchases can signal confidence in the company’s long-term outlook and often support investor sentiment. Ra Capital insider buying article
• Neutral Sentiment: HC Wainwright’s detailed EPS estimates for Q2, Q3, Q4 2026 and FY2026-FY2030 all point to continued losses, but the estimates largely just formalize the company’s early-stage biotech economics rather than changing the story. HC Wainwright earnings estimates on COAG

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.